Material Details

Genome Editing for Inborn Errors of Metabolism: Advancing Towards The Clinic.

01st March, 2017


(51 times downloaded)


Abstact Inborn errors of metabolism (IEM) include many disorders for which current treatments aim to ameliorate disease manifestations, but are not curative. Advances in the field of genome editing have recently resulted in the in vivo correction of murine models of IEM. Site-specific endonucleases, such as zinc-finger nucleases and the CRISPR/Cas9 system, in combination with delivery vectors engineered to target disease tissue, have enabled correction of mutations in disease models of hemophilia B, hereditary tyrosinemia type I, ornithine transcarbamylase deficiency, and lysosomal storage disorders. These in vivo gene correction studies, as well as an overview of genome editing and future directions for the field, are reviewed and discussed herein. KEYWORDS: Inborn errors of metabolism Genome editing CRISPR/Cas9 Zinc-finger nucleases Liver metabolic disorders.

BiotechnologyGene TherapyPediatrics

Damascus University


Click Here

Citation: Schneller J.L., Lee C.M., Bao G. and Venditti Ch.P. Genome editing for inborn errors of metabolism: advancing towards the clinic. BMC Medicine (2017);15:43.